New product information wording: extracts from PRAC recommendations on signals adopted at the 12-15 January 2026 PRAC

Human medicines European public assessment report (EPAR): Imatinib Accord, imatinib, Date of authorisation: 30/06/2013, Revision: 26, Status: Authorised

Minutes - HMA-EMA joint Network Data Steering Group meeting - 15 April 2026

Human medicines European public assessment report (EPAR): Kapruvia, difelikefalin, Date of authorisation: 25/04/2022, Revision: 5, Status: Authorised

Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2026

United for Health: EMA in WorldPride 2026

Human medicines European public assessment report (EPAR): Optison, perflutren, Date of authorisation: 17/05/1998, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Ranluspec, ranibizumab, Date of authorisation: 10/02/2026, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Ozurdex, dexamethasone, Date of authorisation: 26/07/2010, Revision: 22, Status: Authorised

ETF recommends updating COVID-19 vaccines to target XFG variant